Deliberate evasion of narcotic legislation: Trends visualized in commercial mixtures of new psychoactive substances analyzed by GC-solid deposition-FTIR

Abstract

Abstract List-based approaches for judicial control of synthetic drugs inevitably introduce a group of legal highs that do not fall under the scope of legislation but may exhibit similar effects and associated health risks as illicit substances. Differences between controlled and uncontrolled components may be as minor as a single molecular group rearrangement. This phenomenon complicated forensic drug analysis in recent years due to both the rise of new psychoactive substances (NPS), and selectivity limitations of the workhorse gas chromatography-mass spectrometry (GC−MS) technique, especially with respect to ring-isomers. Our study demonstrates the value of GC-solid deposition-Fourier-transform infrared spectroscopy (FTIR) as a complementary technique for NPS identification in multi-drug mixtures. The instrument design using direct deposition of the GC effluent on a cryogenically cooled ZnSe-disk allows for signal enhancement of minor constituents by collecting eluting peaks of multiple GC injections. Highly diagnostic spectra were obtained for all ortho, meta and para-isomers of fluoroamphetamine (FA), fluoromethamphetamine (FMA), methylmethcathinone (MMC) and methylethcathinone (MEC). Combined results of GC−MS and GC-solid deposition-FTIR revealed the presence of up to 11 individual NPS mixed together in liquid samples sold as research chemicals or room odorizer in The Netherlands. Sample compositions rapidly evolved over time with recently controlled substances such as 4-fluoroamphetamine (4-FA), pentedrone, ethylone and 4-methylethcathinone (4-MEC) being replaced by uncontrolled isomers or analogues as 2-fluoroamphetamine (2-FA), 2- or 4-fluoromethamphetamine (2-FMA, 4-FMA) and dimethylone. In 12 different samples all marketed under two brand names, a total of 9 different compositions were identified in samples from 2018 and 2019.